Shield Therapeutics Management
Management criteria checks 2/4
Shield Therapeutics' CEO is Greg Madison, appointed in Jun 2021, has a tenure of 3.08 years. total yearly compensation is $1.32M, comprised of 54.9% salary and 45.1% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth £30.29K. The average tenure of the management team and the board of directors is 3.1 years and 3.2 years respectively.
Key information
Greg Madison
Chief executive officer
US$1.3m
Total compensation
CEO salary percentage | 54.9% |
CEO tenure | 3.1yrs |
CEO ownership | 0.2% |
Management average tenure | 3.1yrs |
Board average tenure | 3.2yrs |
Recent management updates
Recent updates
Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Jun 13Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
May 22Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$1m | US$723k | -US$33m |
Sep 30 2023 | n/a | n/a | -US$40m |
Jun 30 2023 | n/a | n/a | -US$49m |
Mar 31 2023 | n/a | n/a | -US$49m |
Dec 31 2022 | US$1m | US$604k | -US$50m |
Sep 30 2022 | n/a | n/a | -US$39m |
Jun 30 2022 | n/a | n/a | -US$30m |
Mar 31 2022 | n/a | n/a | -US$29m |
Dec 31 2021 | US$585k | US$295k | -US$27m |
Compensation vs Market: Greg's total compensation ($USD1.32M) is above average for companies of similar size in the UK market ($USD367.82K).
Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.
CEO
Greg Madison (57 yo)
3.1yrs
Tenure
US$1,315,605
Compensation
Mr. Gregory P. Madison, also known as Greg, was the Chief Executive Officer and President of Keryx Biopharmaceuticals Inc. since 2015 until April 27, 2018. He served as Chief Executive Officer at Chief Exe...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Executive Director | 3.1yrs | US$1.32m | 0.24% $ 30.3k | |
Co-Founder & Non Executive Director | 16.5yrs | US$47.17k | 1.49% $ 186.4k | |
Chief Financial Officer | less than a year | no data | no data | |
General Counsel & Company Secretary | 6.8yrs | no data | no data | |
Group HR Director | no data | no data | no data | |
Head of Pharmacovigilance & Medical Information | no data | no data | no data | |
Chief Commercial Officer | 1.3yrs | no data | no data | |
Senior Director of People & Culture | no data | no data | no data |
3.1yrs
Average Tenure
56yo
Average Age
Experienced Management: STX's management team is considered experienced (3.1 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Executive Director | 3.1yrs | US$1.32m | 0.24% $ 30.3k | |
Co-Founder & Non Executive Director | 4.1yrs | US$47.17k | 1.49% $ 186.4k | |
Independent Non Executive Chairman | 6yrs | US$119.83k | 0.70% $ 88.0k | |
Non-Executive Director | no data | no data | no data | |
Independent Non-Executive Director | 8.4yrs | US$76.49k | 0.023% $ 2.8k | |
Notable Scientific Advisory Board | no data | no data | no data | |
Independent Non-Executive Director | 3.2yrs | US$47.17k | 0.035% $ 4.4k | |
Notable Scientific Advisory Board | no data | no data | no data | |
Notable Scientific Advisory Board | no data | no data | no data | |
Independent Non-Executive Director | 3.2yrs | US$53.54k | 0.0013% $ 160.2 | |
Notable Scientific Advisory Board | no data | no data | no data |
3.2yrs
Average Tenure
58yo
Average Age
Experienced Board: STX's board of directors are considered experienced (3.2 years average tenure).